ICU Medical (ICUI) shares plummeted 6.85% in Friday's pre-market trading, despite reporting better-than-expected second-quarter earnings. The medical device company's stock faced pressure as investors reacted to a narrowed full-year guidance range and a target price cut by Raymond James.
ICU Medical reported adjusted earnings of $2.10 per share for the quarter ended June 30, significantly surpassing the analysts' expectations of $1.50 per share. Revenue for the quarter came in at $543.6 million, slightly above the consensus estimate of $540.1 million. However, this represents a 6.4% decrease from the same period last year.
Despite the earnings beat, the company revised its full-year adjusted EPS guidance to a range of $6.85 to $7.15, compared to the previous outlook of $6.55 to $7.25. This narrowed range, coupled with Raymond James cutting its target price for ICU Medical from $187 to $180, appears to have overshadowed the positive quarterly results, leading to the sharp decline in stock price during pre-market trading.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。